No Data
No Data
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $MaxCyte(MXCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.0% and a total average return of -4.6% over the past
Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Signing of Strategic Platform License
MaxCyte Signs Strategic Platform License With Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
MaxCyte Director Executes Stock Options and Sells
MaxCyte (LON:MXCT) Shareholders Have Earned a 22% CAGR Over the Last Five Years